Venture - Series Unknown Funded Biotechnology Startups
The 50 rows span rounds closed between September 2022 and November 2025, splitting into two distinct clusters: 29 rounds from September 8 through November…
The 50 rows span rounds closed between September 2022 and November 2025, splitting into two distinct clusters: 29 rounds from September 8 through November 29, 2025, and 21 rounds from September 21 through October 25, 2022, with no records in between. Disclosed round sizes range from $80K (Revel Pharmaceuticals, San Francisco, October 2025) to $261M (Treeline Biosciences, Stamford, October 2022), and seven rounds report undisclosed amounts — a pattern common when "Series Unknown" filings accompany quiet raises or bridge tranches.
San Diego and New York each appear three times — San Diego covers Eclipse Bioinnovations, VST Bio, and Tr1x ($50M, October 2025); New York covers Precision Neuroscience, Volastra Therapeutics, and COTA Healthcare. Fifteen companies are headquartered outside the United States, drawn from 14 countries including India (Molbio Diagnostics, $83M), Netherlands (Leyden Labs, $35M), Switzerland (Anokion, $35M), Ireland (Luminate Medical, $17M), and Spain (Ona Therapeutics and Highlight Therapeutics), demonstrating that the "Series Unknown" designation is not confined to US-centric venture markets.
Most recent rounds
50 shownRelated listings
Frequently asked
What are the largest disclosed rounds in this dataset?
Treeline Biosciences (Stamford, Connecticut) raised $261M in October 2022, followed by Moderna Therapeutics (Cambridge, Massachusetts) at $250M and Enliven Therapeutics (Boulder, Colorado) at $165M, all three closing within the same two-week window in October 2022. Among the 2025-dated rounds, Ensoma (Boston) led at $53M in September and Tr1x (San Diego) followed at $50M in October.
Which cities show up most often among these biotech companies?
San Diego and New York each appear three times. San Diego is represented by Eclipse Bioinnovations, VST Bio, and Tr1x; New York by Precision Neuroscience, Volastra Therapeutics, and COTA Healthcare. Cambridge, Massachusetts and San Francisco each appear twice.
How many rounds have undisclosed amounts?
Seven of the 50 rounds list undisclosed amounts: Proteine Resources (Poland), Renewal Bio (Israel), Precision Neuroscience (New York), Thryv Therapeutics (Canada), COTA Healthcare (New York), MycoWorks (Emeryville, California), and Colossal Biosciences (Dallas, Texas).
How much non-US activity appears in this segment?
Fifteen companies are headquartered outside the United States, spanning 14 countries. Notable disclosed rounds include Molbio Diagnostics (India, $83M), Leyden Labs (Netherlands, $35M), Anokion (Switzerland, $35M), Luminate Medical (Ireland, $17M), MISSION Therapeutics (UK, $13M), and Cellcolabs (Sweden, $12M). Spain appears twice with Ona Therapeutics (Barcelona) and Highlight Therapeutics (Paterna).
What is the smallest disclosed round on the list, and are there other micro-rounds present?
Revel Pharmaceuticals (San Francisco) raised $80K in October 2025, the smallest disclosed figure in the dataset. Three other rounds fall below $500K: MyoGene Bio ($400K, Los Angeles), JuneBrain ($450K, Washington DC), and ImmunoProfile ($230K, Naples), indicating that the 'Series Unknown' classification spans a wide spectrum from pre-revenue seed-scale checks to nine-figure growth rounds.
Do the round dates in this dataset cluster in any particular period?
The 50 rows split into two distinct date bands: 29 rounds dated between September 8 and November 29, 2025, and 21 rounds concentrated in the September 21–October 25, 2022 window, with no records from the roughly 34-month period in between. Researchers building outreach lists or trend analyses should account for this clustering when drawing inferences about cadence or momentum.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.